Figure 4
From: Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson’s disease
Plasma miR-133b (a) and miR-221-3p (b) expression in early-stage PD (modified H-Y stage 1–2.5, n = 18), advanced-stage PD (modified H-Y stage 3–5, n = 9) and healthy controls (n = 15) from cohort 2. ROC analysis of plasma miR-133b (c), miR-221-3p (d) and their combination (e) for discriminating patients with early-stage PD from healthy controls in cohort 2. The ANOVA with post-hoc was used to evaluate differences between groups. Data are presented as the means ± SEMs. The results are indicated as **adjust p value < 0.01 and *adjust p value < 0.05. PD, Parkinson’s disease.
